REpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study
- Conditions
- Intra Cerebral HemorrhageICH - Intracerebral HemorrhageICHHemorrhageStrokeClot (Blood); BrainClot BloodCognitive DeclineCognitive ImpairmentSurvivorship
- Registration Number
- NCT05611918
- Lead Sponsor
- Johns Hopkins University
- Brief Summary
The investigators propose to perform serial detailed cognitive, motor, behavioral, and blood collection follow-up using longitudinal structured telephone interviews of an anticipated 350 ICH survivors enrolled in Minimally Invasive Surgery Plus Alteplase for Intracerebral Hemorrhage Evacuation (MISTIE) III and ENRICH trials to identify specific cognitive and motor impairment and to perform RNA sequencing to evaluate for evidence of chronic inflammation. The investigators' expected sample size in 2022 accounts for mortality attrition of 10%/year.
- Detailed Description
The REASSESS study will conduct long-term cognitive, functional, and neuropsychiatric performance assessments to determine if evacuation of spontaneous intracerebral hemorrhage (ICH) reduces the risk of later cognitive decline in the ageing brain. This study will compare rates of cognitive decline under two treatment strategies for intracerebral hemorrhage: the use of minimally invasive surgery with two similar techniques as performed in the MISTIE III and ENRICH trials, and the current standard of care using data from controls in MISTIE III and ENRICH and comparative data from The Ethnic/Racial Variations of ICH (ERICH) study (U-01-NS067963) extended into the ERICH-Longitudinal study (R01-NS093870) which followed over 900 of ERICH cases with serial cognitive examinations.
Recruitment & Eligibility
- Status
- ENROLLING_BY_INVITATION
- Sex
- All
- Target Recruitment
- 350
- Participants in the study must be survivors enrolled in MISTIE III and ENRICH trials at end of each trial's final follow-up (day 365 in MISTIE III and day 180 in ENRICH). Relatives of known survivors that are found to be deceased since the end of each trial will be interviewed to capture relevant data.
- None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine if surgical clot reduction after ICH reduces the risk of progressive cognitive decline. 24 months Primary outcome measure is the rate of cognitive decline which is based on a composite measure of global cognition using the National Institute on Aging Genetics Initiative for Late Onset Alzheimer Disease (NIA-LOAD) Battery.
Clot reduction measure will be obtained from semi-automated computerized volumetrics using the OsiriX software.
National Institute on Aging Genetics Initiative for Late Onset Alzheimer Disease (NIA-LOAD) Battery is a 7-measure cognitive testing battery to assess change in episodic, semantic, and working memory in community-dwelling older persons with broad ability levels.
- Secondary Outcome Measures
Name Time Method To determine if there is a long-term benefit in survival and functional outcome from minimally invasive surgery whether or not cognitive decline occurs 24 months Survival and poor functional outcome (Modified Rankin Score (mRS) 4-6) will be calculated separately for cases with \<=20 mL and \>20 mL volume. We will use statistical modeling similar to Aim 1 to compute and calculate differences in hazard ratios for risk of mortality and poor outcome among \<=20 mL and \>20 mL survivors. We will assess interaction between cognitive decline and functional performance decline to evaluate whether these decline together.
Secondary outcome measures include the following: Modified Rankin Scale score (mRS), NIH Stroke Scale (NIHSS), Motor Assessment Scale (MAS), Western Aphasia Battery (WAB), Mini Mental Status Exam (MMSE), Barthel Index (BI), De Jong Gierveld Loneliness Scale, EuroQol 5 Dimension (EQ-5D), Activities of Daily Living (ADL) and fall history, Telephone Interview for Cognitive Status (TICS), Informant Questionnaire on Cognitive Decline in the Elderly (IQ-CODE) and Center for Epidemiological Studies Depression (CES-D).
Trial Locations
- Locations (26)
Johns Hopkins Hospital
🇺🇸Baltimore, Maryland, United States
CommonSpirit (formerly Mercy San Juan Medical Center; dignity health)
🇺🇸Chicago, Illinois, United States
Mayo Clinic, Jacksonville
🇺🇸Jacksonville, Florida, United States
Washington University in St. Louis, School of Medicine
🇺🇸Saint Louis, Missouri, United States
University of Cincinnati
🇺🇸Cincinnati, Ohio, United States
University of Texas, Houston Health Science Center
🇺🇸Houston, Texas, United States
University of Texas Health Science Center at San Antonio
🇺🇸San Antonio, Texas, United States
University of Illinois at Chicago
🇺🇸Chicago, Illinois, United States
Hennepin Healthcare Research Institute
🇺🇸Minneapolis, Minnesota, United States
University of Maryland Baltimore
🇺🇸Baltimore, Maryland, United States
Inova Health System Foundation
🇺🇸Fairfax, Virginia, United States
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States
Scripps Health
🇺🇸La Jolla, California, United States
Stanford University
🇺🇸Stanford, California, United States
University of New Mexico
🇺🇸Albuquerque, New Mexico, United States
Rutgers - Robert Wood Johnson Medical School
🇺🇸Piscataway, New Jersey, United States
University of Alabama at Brimingham
🇺🇸Birmingham, Alabama, United States
Henry Ford Health System
🇺🇸Detroit, Michigan, United States
Dignity Health component - St. Joseph's Hospital and Medical Center
🇺🇸Sacramento, California, United States
University of Louisville
🇺🇸Louisville, Kentucky, United States
Yale University
🇺🇸New Haven, Connecticut, United States
University of Michigan
🇺🇸Ann Arbor, Michigan, United States
Wake Forest University Health Sciences
🇺🇸Winston-Salem, North Carolina, United States
Albert Einstein Montefiore
🇺🇸Bronx, New York, United States
Thomas Jefferson University
🇺🇸Philadelphia, Pennsylvania, United States
University of Kansas Medical Center
🇺🇸Fairway, Kansas, United States